Results 261 to 270 of about 39,211 (299)
Some of the next articles are maybe not open access.
2009
Pharmacogenomics encompasses several major areas including the identification and analysis of variations of DNA and RNA that affect the efficacy and toxicity of drug therapy. It represents an integration of analytical approaches including DNA and RNA detection and quantitation which may be applied to either candidate genes or a global genome analysis.
Shilong, Zhong, Marjorie, Romkes
openaire +2 more sources
Pharmacogenomics encompasses several major areas including the identification and analysis of variations of DNA and RNA that affect the efficacy and toxicity of drug therapy. It represents an integration of analytical approaches including DNA and RNA detection and quantitation which may be applied to either candidate genes or a global genome analysis.
Shilong, Zhong, Marjorie, Romkes
openaire +2 more sources
2005
So far no pharmacogenetic/genomic study has been conducted specifically for anxiety disorders. Some of the presented results, however, do pertain to such disorders. For example, pharmacokinetic aspects of antidepressant drug therapy likely also apply to patients with anxiety disorders, and several genetic polymorphisms in the cytochrome P450 (CYP) gene
E B, Binder, F, Holsboer
openaire +2 more sources
So far no pharmacogenetic/genomic study has been conducted specifically for anxiety disorders. Some of the presented results, however, do pertain to such disorders. For example, pharmacokinetic aspects of antidepressant drug therapy likely also apply to patients with anxiety disorders, and several genetic polymorphisms in the cytochrome P450 (CYP) gene
E B, Binder, F, Holsboer
openaire +2 more sources
Pharmacogenomics Journal, 2005 Pharmacogenomics would be instrumental for the realization of personalized medicine in coming decades. Efforts are evident to clarify the potential bioethical, societal, and legal implications of key pharmacogenomics-based technologies projected to be ...
Shun Wong +2 more
exaly +2 more sources
Pharmacogenomics, 2015
Glinides, including repaglinide, nateglinide and mitiglinide, are a type of fasting insulin secretagogue that could help to mimic early-phase insulin release, thus providing improved control of the postprandial glucose levels. Glinides stimulate insulin secretion by inhibiting ATP-sensitive potassium channels in the pancreatic β-cell membrane. Although
Miao, Chen, Cheng, Hu, Weiping, Jia
openaire +2 more sources
Glinides, including repaglinide, nateglinide and mitiglinide, are a type of fasting insulin secretagogue that could help to mimic early-phase insulin release, thus providing improved control of the postprandial glucose levels. Glinides stimulate insulin secretion by inhibiting ATP-sensitive potassium channels in the pancreatic β-cell membrane. Although
Miao, Chen, Cheng, Hu, Weiping, Jia
openaire +2 more sources
2022
Historically genetics has not been considered when prescribing drugs for children. However, it is clear that genetics are not only an important determinant of disease in children but also of drug response for many important drugs that are core agents used in the therapy of common problems in children. Advances in therapy and in the ethical construct of
Michael J, Rieder +1 more
openaire +2 more sources
Historically genetics has not been considered when prescribing drugs for children. However, it is clear that genetics are not only an important determinant of disease in children but also of drug response for many important drugs that are core agents used in the therapy of common problems in children. Advances in therapy and in the ethical construct of
Michael J, Rieder +1 more
openaire +2 more sources
Pharmacogenomics of hypertension
Current Opinion in Nephrology and Hypertension, 2003The emerging field of pharmacogenomics has the potential to fundamentally change the management of essential hypertension, a common, perhaps polygenic syndrome characterized by substantial inter-individual variability in drug responsiveness. As understanding of sequence diversity in the human genome progresses, the prospect grows for tailoring the ...
Peter E, Cadman, Daniel T, O'Connor
openaire +2 more sources
The pharmacogenomics of osteosarcoma
The Pharmacogenomics Journal, 2016Osteosarcoma (OS), the most common malignant tumor of bone, is presently treated with multidrug neoadjuvant chemotherapy protocols, which allow to cure 60-65% of patients but also induce toxicity events that cannot be predicted or efficiently prevented.
M, Serra, C M, Hattinger
openaire +2 more sources
Pharmacogenomics of Antiretrovirals
Recent Patents on Anti-Infective Drug Discovery, 2008HIV infection is a serious but treatable disease, yet current treatment is limited by development of resistance and high rates of adverse drug reactions. Antiretroviral therapy is especially suitable for pharmacogenomic investigation as both drug exposure and treatment response can be reliably measured.
openaire +3 more sources
The pharmacogenomics of epilepsy
Expert Review of Neurotherapeutics, 2015Genetic factors contribute to the high interindividual variability in response to antiepileptic drugs. However, most genetic markers identified to date have limited sensitivity and specificity, and the value of genetic testing in guiding antiepileptic drug (AED) therapy is limited.
FRANCO, VALENTINA, PERUCCA, EMILIO
openaire +3 more sources
Expert Opinion on Pharmacotherapy, 2009
Circulatory disease accounts for fifteen million deaths each year, of which stroke accounts for four and a half million- with an estimated nine million stroke survivors annually. The overall incidence rate of stroke is 2 to 2.5 per thousand adults with an approximate prevalence of 5 per thousand and an estimated 5-year risk of stroke recurrence of 15 ...
Billeci AM +2 more
openaire +3 more sources
Circulatory disease accounts for fifteen million deaths each year, of which stroke accounts for four and a half million- with an estimated nine million stroke survivors annually. The overall incidence rate of stroke is 2 to 2.5 per thousand adults with an approximate prevalence of 5 per thousand and an estimated 5-year risk of stroke recurrence of 15 ...
Billeci AM +2 more
openaire +3 more sources